<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0360">
 <label>11</label>
 <element-citation publication-type="journal" id="sbref0360">
  <person-group person-group-type="author">
   <name>
    <surname>Acanfora</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Ciccone</surname>
    <given-names>M.M.</given-names>
   </name>
   <name>
    <surname>Scicchitano</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Acanfora</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Casucci</surname>
    <given-names>G.</given-names>
   </name>
  </person-group>
  <article-title>Neprelysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): Rationale for adoption in SARS-CoV-2 patients</article-title>
  <source>Eur Heart J Cardiovasc Pharmacother</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1093/ehjcvp/pvaa028</pub-id>
 </element-citation>
</ref>
